Vaccination Future: An In-Depth Look at the Travel Vaccine Market from 2024 to 2032

Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) — The “Travel Vaccines Market Forecast 2024-2032” report has been incorporated into ResearchAndMarkets.com’s portfolio.

The worldwide travel vaccines market achieved a valuation of USD 3.87 billion in 2023. It is projected to expand at a vigorous CAGR of 10.7% during the forecast timeline of 2024-2032, potentially reaching around USD 9.67 billion by 2032. This expansion is propelled by the increasing prevalence of infectious and travel-associated diseases such as Japanese encephalitis, meningitis, diphtheria, and yellow fever, which collectively stimulate the demand for effective vaccination options.

This industry analysis delivers an extensive quantitative evaluation of various market segments, historical and contemporary market trends, market predictions, and the dynamics influencing the global travel vaccines market from 2017 to 2032.

• The research document provides the most recent insights on market drivers, challenges, and prospects within the global travel vaccines industry.
• The analysis delineates both leading and rapidly growing regional markets, facilitating stakeholders in pinpointing essential country-level markets in each region.
• Porter’s five forces framework assists stakeholders in evaluating the influence of new entrants, competitive dynamics, supplier power, buyer power, and the risk of substitutes. It aids stakeholders in analyzing the competition within the global travel vaccines sector and its overall appeal.
• The competitive landscape segment empowers stakeholders to comprehend their competitive surroundings and presents insights into the current standings of major market players.

Market Drivers

Escalating Global Travel: The dramatic increase in international travel for business, leisure, and educational purposes is a key driver for the travel vaccines sector. As individuals travel to areas where endemic diseases are common, the necessity for vaccines to avert illness escalates, ensuring that travellers are safeguarded during their journeys. This phenomenon is especially evident in locales with a high occurrence of infectious diseases, where vaccination is frequently a requirement for entry or advised by health entities.

Government Health Programs: Nations across the globe are increasingly executing health policies that either promote or mandate vaccinations for travellers, especially concerning diseases that pose considerable public health risks. These initiatives, often manifesting as travel warnings or entry prerequisites, significantly enhance the uptake of travel vaccines, bolstering public health safety and minimizing the transmission of infectious diseases across borders.

Progress in Vaccine Technology: Innovations in vaccine development, particularly the formulation of combination vaccines that offer protection against multiple diseases, are rendering vaccines more efficient, safer, and convenient for travellers. These advancements are encouraging greater uptake, as they decrease the number of injections necessary and provide broader immunity, subsequently boosting compliance among travellers who might otherwise skip multiple vaccinations.

Market Challenges

Vaccine Reluctance: In spite of the availability and established effectiveness of vaccines, vaccine reluctance poses a substantial obstacle. Misinformation and apprehensions regarding side effects can dissuade travellers from getting vaccinated, adversely affecting market growth.

Regulatory Obstacles: Managing the intricate regulatory framework for vaccines across different nations can postpone market entry and elevate costs for vaccine producers. Diverse regulatory prerequisites make adherence a considerable challenge.

Distribution Logistical Hurdles: The distribution of vaccines, particularly to remote or underprivileged areas, presents challenges due to the necessity for cold chain storage and transportation. Ensuring that vaccines maintain their efficacy during transport is a vital consideration.

Future Opportunities

Creation of Universal Vaccines: Exploration into universal vaccines that safeguard against multiple strains or varieties of a virus indicates a considerable growth opportunity. Such vaccines may simplify travel health protocols and lessen the amount of vaccinations needed for global travel.

Innovations in Vaccine Administration: Advancements in vaccine delivery, such as needle-free methods or oral vaccines, could enhance vaccine uptake by making the inoculation process less invasive and more convenient for travellers.

Rising Demand for Personalised Vaccination Solutions: The increasing desire for personalized healthcare extends to travel vaccines, with travellers looking for customized vaccination plans based on their unique travel agendas and health requirements. This trend may propel the development of tailored vaccine options.

Market Trends

Shift Towards Combination Vaccines: There is a notable trend towards the utilization of combination vaccines within the travel vaccines sector. Combination vaccines deliver protection against multiple ailments in a single dose, rendering them more convenient for travellers and amplifying vaccination rates. This trend is particularly robust in regions where numerous vaccinations are mandated for safe travel, as it simplifies the vaccination procedure and reduces the number of injections required.

Adoption of Digital Health Passports: With the continuous digitization of healthcare, digital health passports that monitor vaccination status are increasingly becoming standard. These digital instruments enable travellers to easily verify their vaccination status, promoting smoother international travel and improving adherence to travel health guidelines.

Boosted Investment in Vaccine R&D: Both government and private entities are heightening their investments in vaccine research and development, especially in response to emerging global health challenges. This trajectory is anticipated to propel the introduction of new and more effective travel vaccines in the coming years.

Growth of Travel Health Clinics: The proliferation of travel health clinics, particularly in metropolitan areas and close to major transport hubs, is simplifying access to vaccines for travellers. These clinics typically provide a one-stop resource for

Travel health requirements, such as immunizations, travel guidance, and health evaluations, are plays a vital role in the overall expansion of the travel vaccines market.

Travel Vaccines Market Classification

Market Division by Composition

The market is categorized by composition into single vaccines and combination vaccines. Single vaccines are intended to safeguard against a singular illness and are still commonly utilized for their precise targeting attributes. Conversely, combination vaccines are gaining popularity due to their practicality, providing protection against several diseases in a single injection. This segment is anticipated to experience notable growth as it addresses the needs of travelers requiring multiple vaccinations, simplifying the immunization procedure.

Market Division by Disease

The market classification of travel vaccines by illness encompasses hepatitis A, DPT, yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, and others. Vaccines for hepatitis A and B are highly sought after owing to their efficacy and the commonality of these ailments in numerous travel locations. Vaccines for yellow fever and typhoid are also crucial, particularly for travelers heading to areas where these diseases are prevalent. The ‘others’ category comprises a variety of vaccines for less frequent but equally significant illnesses, signifying the diversity and intricacy of travel health needs.

Market Division by Region

The regional market classification includes North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is at the forefront of the market, propelled by elevated travel frequencies and robust healthcare systems. Europe closely follows, boasting a well-established framework for travel vaccinations. The Asia Pacific region is witnessing rapid expansion attributed to increasing outbound travel and heightened awareness of health risks associated with travel. Latin America, as well as the Middle East and Africa, are burgeoning markets, presenting substantial potential as international travel escalates and healthcare infrastructure enhances.

Competitive Landscape

The competitive framework of the global travel vaccines market features prominent companies such as GlaxoSmithKline plc, Merck & Co., Sanofi SA, and Pfizer Inc., which dominate the landscape with extensive vaccine portfolios and strong international distribution channels. CSL Limited, Bavarian Nordic AS, and F. Hoffmann-La Roche Ltd also play significant roles, concentrating on vaccine development and market growth.

Firms like Abbott Laboratories, AstraZeneca plc, and Janssen Pharmaceuticals significantly impact market expansion through innovation and strategic alliances. Valneva SE, BioNTech SE, and Sinovac Biotech Ltd are emerging contenders, enhancing rivalry and propelling further advancements within the travel vaccines market.

Key Characteristics

Major Companies Featured in this Travel Vaccines Market Report

• GlaxoSmithKline plc
• Merck & Co.
• Sanofi SA
• Pfizer Inc.
• CSL Limited
• Bavarian Nordic AS
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• AstraZeneca plc
• Janssen Pharmaceuticals
• Valneva SE
• BioNTech SE
• Sinovac Biotech Ltd.

For additional details regarding this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com serves as the premier provider of global market research reports and market statistics. We furnish you with the latest information on worldwide and regional markets, principal industries, leading companies, new products, and emerging trends.